CME Empowerment Series 2025
The Continuing Medical Education (CME) Empowerment Series III is intended to offer insights into advanced therapeutic strategies for cancer, enabling medical professionals to acquire, share and exchange knowledge and clinical experience.
Beyond knowledge sharing, the series aims to foster collaborative working relationships, build a vibrant medical community and enhance competencies in delivering patient care.
The cornerstone of treatment for advanced prostate cancer is androgen deprivation therapy (ADT). In metastatic castration-sensitive prostate cancer (mCSPC), a large body of data supports early intensification of treatment by adding a novel hormonal agent (NHA) and/or chemotherapy.
Genomic testing should be offered to all patients with metastatic castration-resistant prostate cancer (mCRPC) to identify those with DNA repair pathway alterations or loss of mismatch repair protein expression, who may benefit from treatment with PARP inhibitors and immunotherapy, respectively.
The key focus of the session is on the role of targeting prostate-specific membrane antigen (PSMA). PSMA is widely expressed on the surface of most prostate cancer cells and can be harnessed to deliver PSMA-based radioligand therapy in mCRPC patients who have failed novel hormonal agents and/or chemotherapy. Data on treatment benefits and subgroups who derive greater benefit from this approach will be discussed.
This event is accredited by Singapore Medical Council for 1 CME point.Speakers and Panelists
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Consultant Nuclear Medicine Physician
Parkway Radiology
This CME event is supported by Parkway Radiology and in collaboration with Novartis.
DATE
Tuesday, 27 May 2025
TIME
7PM - 9PM SGT
VENUE
FLUTES Restaurant @
Guoco Midtown House
The Chamber Room
120 Beach Road,
#01-02 Midtown House
Singapore 189769
Colorectal cancer (CRC) remains a leading cancer globally, with early detection and treatment playing a crucial role in improving patient outcomes.
In this “Hi Doc” CME Series III, we’ll be learning the latest approaches to CRC management, focusing on diagnostic procedures, surgical techniques and medical treatments.
Understand the role of colonoscopy in early detection and screening for CRC, surgical management, including the latest minimally invasive procedures and strategies for optimising patient recovery and the medical management for both localised and metastatic CRC.
Speakers
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Consultant Colorectal & General Surgeon
Ho Kok Sun Colorectal
This CME event is supported by Pierre Fabre.
DATE
Saturday, 12 April 2025
TIME
2PM - 3PM SGT
FORMAT
Hybrid Event